Abstract:Abstract Short or small interfering RNAs (siRNAs) and microRNA (miRNAs) are molecules similar in size and function able to inhibit gene expression based on their complementarity with mRNA sequences, inducing the degradation of the transcript or the inhibition of their translation. siRNAs bind specifically to a single gene location by sequence complementarity and regulate gene expression by specifically targeting transcription units via posttranscriptional gene silencing. miRNAs can regulate the expression of different gene targets through their imperfect base pairing. This process - known as RNA interference (RNAi) - modulates transcription in order to maintain a correct physiological environment, playing a role in almost the totality of the cellular pathways. siRNAs have been evolutionary evolved for the protection of genome integrity in response to exogenous and invasive nucleic acids such as transgenes or transposons. Artificial siRNAs are widely used in molecular biology for transient silencing of genes of interest. This strategy allows to inhibit the expression of any target protein of known sequence and is currently used for the treatment of different human diseases including cancer. Modifications and rearrangements in gene regions encoding for miRNAs have been found in cancer cells, and specific miRNA expression profiles characterize the developmental lineage and the differentiation state of the tumor. miRNAs with different expression patterns in tumors have been reported as oncogenes (oncomirs) or tumor-suppressors (anti-oncomirs). RNA modulation has become important in cancer research not only for development of early and easy diagnosis tools but also as a promising novel therapeutic approach. Despite the emerging discoveries supporting the role of miRNAs in carcinogenesis and their and siRNAs possible use in therapy, a series of concerns regarding their development, delivery and side effects have arisen. In this review we report the biology of miRNAs and siRNAs in relation to cancer summarizing the recent methods described to use them as novel therapeutic drugs and methods to specifically deliver them to cancer cells and overcome the limitations in the use of these molecules.

Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics

MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside

Small Interfering RNA-based Molecular Therapy of Cancers

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy

Small interfering RNA for experimental cancer therapy.

miRNA: A Promising Therapeutic Target in Cancer

Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

Non-coding RNAs and potential therapeutic targeting in cancer

Nanoparticle‐Mediated Sirna Delivery and Multifunctional Modification Strategies for Effective Cancer Therapy

Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy

MicroRNAs in non‐small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

A novel strategy for cancer gene therapy: RNAi

Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer

Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics

Noncoding RNA for Cancer Gene Therapy.

Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells-Function and Therapeutic Potential

Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?

An update on RNA interference-mediated gene silencing in cancer therapy.